Achieve Life Sciences, Inc. (ACHV) Stock

Achieve Life Sciences, Inc. (ACHV) is a Healthcare stock trading at $4.83 (as of 2026-06-18), with a market capitalization of $505.08M and a trailing P/E of -5.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Valuation — source: SEC EDGAR (first-party)
Price	$4.83
Market Cap	$505.08M
P/E Ratio	-5.2
EV / EBITDA	-9.9
Price / Book	53.07
Price / Sales	385.50
DCF Value (model)	$-8.00
DCF Upside vs Price	-265.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$1.50M
Net Margin	-3655.4%
Return on Equity	-486.9%
Current Ratio	2.62
Revenue Growth (YoY)	-36.5%
EPS Growth (YoY)	0.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	2.56 (grey)

Valuation vs Sector & Industry
Stock P/E	-5.2
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-124.6%
vs Industry	-129.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	FRANKLIN RESOURCES INC ($12.85M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Richard A. Stewart
Employees	25
Country	CA
IPO Date	1997-03-19

Related Companies (Business model: Clinical Labs / CRO Services; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.